NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

不得分发给美国新闻专线服务或在美国境内传播

TORONTO, March 21, 2025 (GLOBE NEWSWIRE) --  Conavi Medical Corp.

多伦多，2025年3月21日（环球新闻社）-- Conavi Medical Corp.

(TSXV: CNVI; OTC: CNVIF)

（TSXV：CNVI；OTC：CNVIF）

(“

(“

Conavi

康纳维

” or the “

“或者“

Company

公司

”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to provide an update in respect of its previously announced public offering (the “

“），一家专注于设计、制造和营销成像技术以指导常见微创心血管手术的商业阶段医疗设备公司，欣然提供有关其此前宣布的公开发行（“

Offering

供品

”). The Company expects that the Offering will now proceed as an offering of common shares of the Company (“

“）。公司预计此次发行现在将作为公司普通股的发行进行（“

Common Shares

普通股

”) (or pre-funded common share purchase warrants (“

”）（或预先出资的普通股购买权证（“

Pre-Funded Warrants

预融资权证

” and, together with the Common Shares, the “

”和普通股一起，“

Securities

证券

”) of the Company in lieu of Common Shares). The number of Securities to be distributed, the price of each Security and the size of the Offering will be determined by negotiation between the Company and the Agent (as defined below) in the context of the market with final terms to be determined at the time of pricing..

“）的公司代替普通股）。待分配证券的数量、每种证券的价格和发行规模将由公司与代理（定义见下文）根据市场情况进行协商确定，最终条款将在定价时确定。。

The Company filed an amended and restated preliminary short form prospectus (the “

公司提交了一份修订及重述的初步简短形式招股说明书（“

A&R Prospectus

艺人与曲目展望

”) on March 20, 2025 with the securities regulatory authorities in the provinces of Alberta, British Columbia and Ontario, amending and restating the preliminary short form prospectus filed on January 29, 2025.

”)于2025年3月20日提交给阿尔伯塔省、不列颠哥伦比亚省和安大略省的证券监管机构，修订并重述了2025年1月29日提交的初步简式招股说明书。

The Company intends to use the net proceeds from the Offering to advance and complete the development and pre-clinical testing of its Novasight 3.0 technology, with the goal of submitting 510(k) clearance application to the U.S. Food and Drug Administration in Q3 of calendar 2025. The Company also intends to use the net proceeds for working capital and other general corporate purposes..

公司打算将发售所得净收益用于推进并完成其Novasight 3.0技术的开发和临床前测试，目标是在2025年日历年度第三季度向美国食品药品监督管理局提交510(k)许可申请。公司还计划将所得净收益用于营运资金及其他一般企业用途。

The Offering is expected to be completed pursuant to the terms and conditions of an agency agreement (the “

预计本次发售将根据代理协议（“

Agency Agreement

代理协议

”) to be entered into between the Company and Bloom Burton Securities Inc. (the “

“）由公司与Bloom Burton Securities Inc.（“

Agent

代理

”).

”").

The Offering is expected to close on or about March 31, 2025, or such other date as may be mutually agreed to by the Company and the Agent (the “

预计此次发行将在2025年3月31日或公司与代理机构可能共同商定的其他日期（“完成日期”）前后结束。

Closing Date

截止日期

”). The Offering is subject to the Company and the Agent entering into the Agency Agreement and the satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals, including approval of the TSX Venture Exchange (“

”）。此次发行取决于公司与代理机构签订代理协议，并满足常规的交割条件，包括收到所有必要的监管和证券交易所的批准，包括多伦多创业交易所（“TSX Venture Exchange”）的批准（“

TSXV

TSXV

”).

”

In addition, the Securities are anticipated to be offered by way of private placement in certain jurisdictions outside of Canada pursuant to and in compliance with applicable securities laws.

此外，预计证券将在加拿大境外的某些司法管辖区根据适用的证券法通过私募方式发行。

This press release is not an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “.

本新闻稿并非在任何法域出售或招揽购买证券的要约，在该法域中，此类要约、招揽或出售在根据该法域的证券法进行资格认证或注册之前是非法的。所发售的证券尚未且不会根据经修订的1933年美国证券法（“该法案”）进行注册。

U.S. Securities Act

美国证券法

”), and such securities may not be offered or sold to, or for the account or benefit of, persons in the United States or U.S. persons absent registration or an applicable exemption from U.S. registration requirements. “United States” and “U.S. persons” have the meanings ascribed to them in Regulation S under the U.S.

“），且未在美国注册或未获得美国注册要求的适用豁免时，该等证券不得向美国境内的人士或为美国人士的利益提供或出售。“美国”和“美国人士”具有美国监管条例S中赋予它们的含义。”

Securities Act..

证券法。。

Access to the A&R Prospectus and any amendments to such document will be provided in accordance with securities legislation relating to procedures for providing access to a short form prospectus and any amendment thereto. The A&R Prospectus is accessible on SEDAR+ at www.sedarplus.ca. Alternatively, an electronic or paper copy of the A&R Prospectus and any amendment to such document may be obtained without charge, from the Agent by email at .

根据与提供简式招股说明书及其任何修订版本相关的证券立法程序，将提供查阅A&R招股说明书及该文件的任何修订版本的途径。A&R招股说明书可在SEDAR+网站www.sedarplus.ca上查阅。此外，可免费从代理人处通过电子邮件获取A&R招股说明书及其任何修订版本的电子版或纸质副本。

ECM@bloomburton.com

ECM@bloomburton.com

, by telephone at 416-640-7585 or by providing the contact with an email address or address, as applicable. The A&R Prospectus contains important, detailed information about the Company and the Offering. Prospective investors should read the A&R Prospectus before making an investment decision.

，通过电话416-640-7585联系，或根据适用情况提供电子邮件地址或邮寄地址。A&R招股说明书包含有关公司和发行的重要详细信息。潜在投资者在做出投资决定前应阅读A&R招股说明书。

About Conavi Medical

关于 Conavi Medical

Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries.

Conavi Medical 专注于设计、制造和销售成像技术，以指导常见的心血管微创手术。其获得专利的 Novasight Hybrid™ 系统是首个结合血管内超声 (IVUS) 和光学相干断层扫描 (OCT) 的系统，能够对冠状动脉进行同步且共配准的成像。

The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China’s National Medical Products Administration, and Japan’s Ministry of Health, Labor and Welfare. For more information, visit .

NovaSight混合系统已获得美国食品药品监督管理局（FDA）的510(k)许可，以及加拿大卫生部、中国国家药品监督管理局和日本厚生劳动省的临床使用监管批准。欲了解更多信息，请访问。

http://www.conavi.com/

http://www.conavi.com/

.

。

CONTACT:

联系：

Stefano Picone

斯特凡诺·皮科内

Chief Financial Officer

首席财务官

(416) 483-0100

(416) 483-0100

Notice on forward-looking statements:

前瞻性声明通知：

This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to the anticipated terms and jurisdictions of the Offering; securities offered thereunder; the timing of the Offering, including the anticipated Closing Date; use of proceeds from the Offering; fees anticipated to be paid to the Agent and terms thereof; and regulatory and exchange approvals, including the listing of the common shares offered pursuant to the Offering on the TSXV.

本新闻稿包含有关 Conavi 及其业务的前瞻性信息或适用证券法意义上的前瞻性声明，可能包括但不限于以下方面的声明：发行的预期条款和司法管辖区；根据发行所发售的证券；发行的时间安排，包括预期的截止日期；发行所得款项的用途；预计向代理支付的费用及其条款；以及监管和交易所的批准，包括根据发行所发售的普通股在 TSXV 的上市。

All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”.

所有并非历史事实的陈述或信息，包括但不限于有关未来估计、计划、项目、预测、预测值、目标、假设、期望或对未来表现的信念的陈述，均属于“前瞻性信息或陈述”。

Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” “anticipate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved.

通常但并非总是，前瞻性信息或声明可以通过使用诸如“将”、“意图”、“预期”、“相信”、“计划”、“预计”、“打算”、“估计”、“预期”等词语或这些词语和短语的任何变体（包括否定形式）来识别，或者表明某些行动、事件或结果“可能”、“或许”、“能够”、“可以”、“将会”被采取、发生、导致、产生、或得以实现。

Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect.

此类声明基于公司管理层对当前的预期和未来事件的看法。这些声明基于假设，并受风险和不确定性的影响。尽管管理层认为这些声明所依据的假设是合理的，但这些假设可能被证明是不正确的。

The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of k.

本新闻稿中讨论的前瞻性事件和情况，可能不会发生，并且由于k的原因，可能会有重大差异。

www.sedar.com

www.sedar.com

). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

). 尽管康纳维已试图找出可能导致实际行为、事件或结果与前瞻性陈述中所述内容有重大差异的重要因素，但可能还有其他因素导致行为、事件或结果与预期、估计或计划中的情况有所不同。

Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise..

因此，读者不应过分依赖任何前瞻性声明或信息。任何前瞻性声明均无法得到保证。除非适用的证券法律要求，否则前瞻性声明仅在其作出之日有效，Conavi 不承担任何公开更新或修改任何前瞻性声明的义务，无论是由于新信息、未来事件或其他原因。

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release..

任何监管机构均未批准或不批准本新闻稿的内容。TSX创业交易所及其监管服务提供商（该术语在TSX创业交易所的政策中定义）均不对本新闻稿的充分性或准确性承担责任。